The stock of Insys Therapeutics Inc (NASDAQ:INSY) is a huge mover today! About 657,755 shares traded hands. Insys Therapeutics Inc (NASDAQ:INSY) has declined 11.91% since April 27, 2016 and is downtrending. It has underperformed by 17.14% the S&P500.
The move comes after 9 months negative chart setup for the $853.20 million company. It was reported on Nov, 30 by Barchart.com. We have $11.38 PT which if reached, will make NASDAQ:INSY worth $25.60 million less.
Analysts await Insys Therapeutics Inc (NASDAQ:INSY) to report earnings on February, 28. They expect $0.01 EPS, down 95.45% or $0.21 from last year’s $0.22 per share. INSY’s profit will be $727,366 for 293.25 P/E if the $0.01 EPS becomes a reality.
Insys Therapeutics Inc (NASDAQ:INSY) Ratings Coverage
Out of 4 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Insys Therapeutics has been the topic of 9 analyst reports since August 4, 2015 according to StockzIntelligence Inc. As per Monday, October 10, the company rating was maintained by Jefferies. As per Thursday, August 4, the company rating was maintained by Jefferies. The stock of Insys Therapeutics Inc (NASDAQ:INSY) earned “Hold” rating by Oppenheimer on Tuesday, August 4. As per Tuesday, April 12, the company rating was maintained by Jefferies. The firm has “Buy” rating given on Thursday, April 14 by Janney Capital. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. The firm has “Outperform” rating given on Thursday, September 22 by RBC Capital Markets. Jefferies maintained the shares of INSY in a report on Wednesday, February 24 with “Buy” rating. The firm earned “Buy” rating on Friday, August 14 by Zacks.
According to Zacks Investment Research, “Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company’s cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.”
Insitutional Activity: The institutional sentiment increased to 1.23 in Q2 2016. Its up 0.53, from 0.7 in 2016Q1. The ratio improved, as 22 funds sold all Insys Therapeutics Inc shares owned while 42 reduced positions. 13 funds bought stakes while 32 increased positions. They now own 31.30 million shares or 9.76% less from 34.69 million shares in 2016Q1.
Blackrock Gp Ltd, a United Kingdom-based fund reported 93,015 shares. Morgan Stanley accumulated 0% or 120,736 shares. Globeflex Capital Lp owns 39,624 shares or 0.14% of their US portfolio. The Switzerland-based Swiss Comml Bank has invested 0% in Insys Therapeutics Inc (NASDAQ:INSY). The Wisconsin-based Convergence Invest Limited Company has invested 0.03% in Insys Therapeutics Inc (NASDAQ:INSY). Wealthtrust owns 200 shares or 0% of their US portfolio. State Board Of Administration Of Florida Retirement last reported 0% of its portfolio in the stock. Blackrock Advisors Lc holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 279,631 shares. The Germany-based Commerzbank Aktiengesellschaft Fi has invested 0% in Insys Therapeutics Inc (NASDAQ:INSY). Schwab Charles Invest Mngmt owns 76,119 shares or 0% of their US portfolio. Community Bank Na last reported 0% of its portfolio in the stock. Blackrock Inv Mgmt reported 113,933 shares or 0% of all its holdings. Amer Century accumulated 281,966 shares or 0% of the stock. Ubs Asset Americas has 17,800 shares for 0% of their US portfolio. Teachers Advisors holds 0% of its portfolio in Insys Therapeutics Inc (NASDAQ:INSY) for 35,901 shares.
Insider Transactions: Since June 6, 2016, the stock had 2 insider purchases, and 4 sales for $704,930 net activity. 15,000 shares were sold by STANLEY THEODORE H, worth $270,300. On Friday, November 4 MEYER STEVEN J bought $107,489 worth of the stock or 10,000 shares. $105,853 worth of shares were bought by JOHN N KAPOOR TRUST DATED SEPTEMBER 20 1989 on Friday, August 12. On Tuesday, August 9 the insider BRENNAN DANIEL sold $110,752. 15,000 Insys Therapeutics Inc (NASDAQ:INSY) shares with value of $276,900 were sold by FOURTEAU PATRICK.
More important recent Insys Therapeutics Inc (NASDAQ:INSY) news were published by: Fool.com which released: “Here’s Why Insys Therapeutics Inc. Fell 14.3% in April” on May 10, 2016, also Forbes.com published article titled: “FDA Approves Insys Therapeutics’ 2nd Cannabis-Based Drug”, Businessinsider.com published: “A pharmaceutical company is fighting marijuana legalization because it would …” on September 13, 2016. More interesting news about Insys Therapeutics Inc (NASDAQ:INSY) was released by: Globenewswire.com and their article: “Insys Therapeutics Announces CEO Succession Plan” with publication date: September 21, 2016.
INSY Company Profile
Insys Therapeutics, Inc., incorporated on June 15, 1990, is a commercial-stage specialty pharmaceutical company. The Firm develops and commercializes supportive care products. Subsys is the Company’s marketed product. Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and is a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Firm markets Subsys through its field sales force focused on supportive care physicians in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.